Japanese Encephalitis
[!WARNING] Medical Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. Medical guidelines and best practices change rapidly; users should verify information with current local protocols.
Summary
Japanese Encephalitis (JE) is a vector-borne viral zoonosis that represents the leading cause of vaccine-preventable viral encephalitis in Asia. It is caused by the Japanese encephalitis virus (JEV), a single-stranded RNA flavivirus closely related to West Nile, St. Louis Encephalitis, and Dengue viruses.
The disease is endemic across 24 countries in Southeast Asia and the Western Pacific, putting over 3 billion people at risk. An estimated 68,000 clinical cases occur annually, though this is likely a gross underestimate due to poor surveillance. While less than 1% of infections result in symptomatic neuroinvasive disease, the consequences for those affected are devastating: High Case Fatality Rate (20-30%) and a high rate of permanent neurological sequelae (30-50%) in survivors.
Key Facts
| Feature | Details |
|---|---|
| Pathogen | Japanese Encephalitis Virus (JEV). Family Flaviviridae, Genus Flavivirus. |
| Vector | Culex mosquitoes (Primarily Culex tritaeniorhynchus). |
| Reservoir Hosts | Ardeid birds (Herons, Egrets). |
| Amplifying Hosts | Pigs (Sus scrofa) - develop high viraemia needed to infect mosquitoes. |
| Dead-End Hosts | Humans, Horses (Viraemia is too low to infect mosquitoes). |
| Transmission | Bite of infected mosquito (Zoonotic cycle: Bird-Mosquito-Pig-Mosquito-Human). |
| Incubation | 5 to 15 days. |
| Clinical Attack Rate | < 1% (1 in 250 infections results in encephalitis). |
| Case Fatality Rate | 20% to 30% (Higher in children/elderly). |
| Sequelae | Intellectual impairment, Seizures, Parkinsonism, Paralysis. |
| Vaccine | Yes. Inactivated (IXIARO) and Live-Attenuated (SA 14-14-2). |
| Treatment | Supportive only. No specific antiviral exists. |
Why This Matters Clinically
- Diagnostic Challenge: JE mimics other causes of acute encephalitis (Herpes, Meningitis, Cerebral Malaria). Recognising the "Parkinsonian" features and travel history can save unnecessary treatments.
- Vaccine Preventable: Almost all cases in travellers are preventable. Pre-travel counsel is critical.
- Emerging Threat: Climate change and rice farming expansion are shifting the vector range. Cases have recently occurred in Australia (2022 outbreak), demonstrating its potential for spread.
Understanding the virus structure is key to understanding vaccine targets and serological cross-reactivity.
Classification
- Family: Flaviviridae (from Latin flavus = yellow, due to Yellow Fever).
- Genus: Flavivirus.
- Serogroup: Japanese Encephalitis Serocomplex.
- Includes: West Nile Virus, St. Louis Encephalitis, Murray Valley Encephalitis, Usutu Virus.
- Clinical Significance: This close relationship causes Serological Cross-Reactivity. An ELISA for JE might be false-positive if the patient had Dengue or West Nile. Confirmatory Plaque Reduction Neutralization Test (PRNT) is required.
Structure
JEV is a small (50nm) enveloped virus with a positive-sense single-stranded RNA genome (11kb).
- Structural Proteins:
- C (Capsid): Protects the RNA.
- prM (Membrane): Important for maturation.
- E (Envelope): The critical protein.
- Contains the Receptor Binding Domain.
- Target of Neutralising Antibodies.
- Vaccines (Ixiaro, SA 14-14-2) target this protein.
- Non-Structural Proteins (NS1-NS5):
- NS1: Secreted antigen (used in diagnostics).
- NS3: Protease/Helicase.
- NS5: RNA-dependent RNA Polymerase (Replication).
Genotypes
There are 5 genotypes (GI - GV).
- Genotype III (G3): Historically the dominant strain in Asia. (The SA 14-14-2 vaccine is based on G3).
- Genotype I (G1): Has replaced G3 as the dominant strain in Asia over the last 20 years.
- Genotype V (G5): Originally from Malaysia. Re-emerged recently in Korea.
- Vaccine Implications: Fortunately, current G3-based vaccines (Ixiaro) provide protection against G1. However, protection against G5 is less certain and is an area of active research.
The Transmission Cycle (Enzootic Cycle)
JEV exists in a natural transmission cycle involving mosquitoes and vertebrate hosts.
- Maintenance: The virus circulates between Ardeid birds (Herons, Egrets) and mosquitoes. Birds are the natural reservoir; they migrate and spread the virus.
- Amplification: When infected mosquitoes bite Pigs (domestic or wild), the virus replicates to huge levels in the pig's blood (Amplifying Host). Pigs do not get sick but become "Virus Factories".
- Spillover: Mosquitoes bite viraemic pigs, become highly infectious, and then bite Humans (accidental hosts). In humans, viraemia is low and transient, so we cannot infect new mosquitoes (Dead-End Host).

Vector Ecology
- Primary Vector: Culex tritaeniorhynchus.
- Habitat: Stagnant, warm water. Primarily Rice Paddies and irrigation canals.
- Behaviour: Exophilic (Outdoor biting), Crepuscular/Nocturnal (Bites at dusk and dawn).
- Range: Highly adapted to rural agricultural areas where rice fields and pig farms coexist (The perfect storm).
Geographic Distribution & Regional Burdens
JEV is the leading cause of viral encephalitis in Asia, but the burden varies significantly by region due to vaccination programs and agricultural practices.
| Region | Status | Key Features |
|---|---|---|
| China | Endemic / Controlled | Historically high burden (>10,000 cases/year). Massive vaccination (SA 14-14-2) has reduced incidence by >90%. Now sporadic. |
| India | Hyper-Endemic | Uttar Pradesh & Bihar (Gorakhpur region) see massive annual monsoon outbreaks. High mortality in children. Vaccination initiated but coverage patchy. |
| Vietnam | Endemic | High burden in the Red River Delta (North). Pigs widely kept in backyards ("Pig-Rice Farming"). |
| Thailand | Controlled | Successful national immunization in the 1990s dramatically reduced cases. Now mostly in unvaccinated adults/rural poor. |
| Japan / Korea | Controlled | Rare. Only sporadic cases in unvaccinated elderly or visiting travellers. Pig immunization is practiced. |
| Australia | Emerging | The 2022 Outbreak was a game-changer. Virus spread south to Victoria/NSW due to La Niña floods. Now considered endemic in feral pig populations. |
| Nepal | Endemic | Terai region (lowlands). Hills formerly safe, now seeing cases due to warming climate. |
Vector Ecology: Culex tritaeniorhynchus
The vector is a masterpiece of evolutionary adaptation to rice farming.
1. The "Rice Paddy" Mosquito
- Breeding: Prefers sunlit, clean, stagnant water with low organic content—exactly what a flooded rice field provides.
- Resilience: Can fly up to 5km (long-range wind dispersal aids spread).
- Biting Habits:
- Exophilic: Rests outdoors (unlike Aedes which rests indoors).
- Zoophilic: Prefers biting animals (Cattle > Pigs > Humans). Humans are bitten only when vector density is explosive (Spillover).
- Crepuscular: Biting peaks at dusk (6 PM - 9 PM).
2. Other Vectors
- Culex vishnui group (India).
- Culex gelidus (SE Asia - breeds in dirtier water).
- Culex annulirostris (Australia).
- Aedes species (Rare, but can transmit).
The Role of Climate Change
- Range Expansion: Warming allows vectors to survive at higher altitudes (Nepal/Tibet) and latitudes.
- Rainfall: Heavy monsoons expand breeding sites.
- Flooding: Washes away larvae initially but creates stagnant pools later (Delayed outbreak).
Host Dynamics: The Pig-Bird-Human Nexus
- Pigs (The Amplifier):
- High body temperature (good for virus).
- High turnover (new susceptible piglets born every year = constant fuel).
- Kept close to houses.
- Birds (The Reservoir):
- Herons/Egrets are migratory. They introduce the virus to new areas.
- They are unaffected by the virus.
- Cattle (The "Mosquito Sponge"):
- Mosquitoes love biting cows.
- Cows are dead-end hosts (do not amplify virus).
- Ecological Pearl: Having cattle between pigs and humans can REDUCE transmission (Zooprophylaxis).
- Endemic Zone: From India/Pakistan in the West to Japan/Korea in the East. From Indonesia/Papua New Guinea in the South to Southern Russia in the North.
- Recent Spread: Outbreaks in Australia (Victoria, NSW, Queensland) in 2022 marked a significant range expansion.
- Seasonality:
- Temperate Regions: Summer/Autumn epidemics.
- Tropical Regions: Year-round transmission with peaks in the rainy season.
Mechanism of Neuroinvasion
JEV is neurotropic, meaning it has a specific predilection for invading the central nervous system.
- Peripheral Replication (The "Incubation" Phase):
- Mosquito saliva injects the virus into the dermis.
- Virus infects Langerhans cells (dendritic cells) and migrates to regional lymph nodes.
- Transient Viraemia: Virus spills into blood. In most hosts, neutralising antibodies (IgM) clear it here (Asymptomatic).
- Crossing the Blood-Brain Barrier (BBB):
- If viraemia is high or BBB is compromised/permeable (e.g., in children), the virus crosses via:
- Passive Diffusion: Paracellular transport across endothelial tight junctions.
- Trojan Horse: Inside infected monocytes/macrophages.
- If viraemia is high or BBB is compromised/permeable (e.g., in children), the virus crosses via:
- Neuronal Targeting (Thalamic Tropism):
- Once in the brain, JEV binds to specific receptors (Heat Shock Protein 70, Laminin receptor) concentrated in the Thalamus, Basal Ganglia, and Substantia Nigra.
- This specific localization explains the "Parkinsonian" features (Tremor, Mask-face).
- Cytopathology & Inflammation:
- Direct Lysis: Virus replication kills neurons.
- Bystander Damage: The massive release of cytokines (TNF-a, IL-6) and activation of microglia causes more damage than the virus itself ("Cytokine Storm").
Pathology
- Gross: Cerebral oedema, congestion, and focal haemorrhages in the thalami.
- Microscopic: Perivascular cuffing (lymphocytes), Neuronophagia (microglia eating dead neurons), and "Glial Knots".
The classic presentation evolves through three distinct stages.
Clinical Scenario: The Backpacker
A 24-year-old student returns from a 2-month trip to rural Thailand and Vietnam. He presents with fever, headache, and confusion. On examination, he has a mask-like face and cogwheel rigidity.
Key Teaching Points
- The travel history (rural Asia) + Encephalitis is the clue.
- The **Parkinsonian signs** (mask face, rigidity) are highly specific for JE because the virus targets the Basal Ganglia and Thalamus.
- MRI showing **bilateral thalamic hyperintensity** confirms the clinical suspicion.
Stage 1: Prodrome (Days 1-3)
Often non-specific, leading to misdiagnosis as "Viral fever" or "Flu".
Stage 2: Acute Encephalitic Stage (Days 3-7)
The virus hits the CNS. Rapid deterioration of GCS.
Stage 3: Convalescence or Sequelae (Weeks to Months)
Vital Signs
- Temperature: Often > 40°C (Hyperpyrexia).
- Respiratory Pattern: Cheyne-Stokes or Central Neurogenic Hyperventilation (Midbrain compression).
- Cushing’s Reflex: Bradycardia + Hypertension (Sign of raised ICP).
Neurological Exam
- GCS: Documentation of baseline is critical.
- Meningism: Neck stiffness, Kernig’s, Brudzinski’s (Positive in 50%).
- Fundoscopy: Papilloedema (Blurring of disc margins).
- Tone:
- Rigidity: "Lead-pipe" or "Cogwheel" (Extrapyramidal).
- Spasticity: Clasp-knife (Pyramidal).
- Flaccidity: Lower Motor Neuron (Anterior Horn Cell).
- Brainstem Reflexes: Pupillary light reflex, Oculocephalic (Doll's eye). Loss = Poor prognosis.
Differentiating JE from other causes of Acute Encephalitis Syndrome (AES) is difficult but critical.
| Condition | Key Differentiators | Investigation | Actions |
|---|---|---|---|
| Herpes Simplex Encephalitis (HSV) | Fronto-temporal involvement (Personality change, Dysphasia). No Parkinsonism. | MRI: Temporal Lobe hyperintensity. CSF: PCR positive. | Start High Dose IV Acyclovir immediately. |
| Cerebral Malaria | Falciparum malaria. Retinopathy (white patches). Splenomegaly. | Blood Film (Thick/Thin). Rapid Antigen Test. | IV Artesunate. |
| Nipah Virus | Exposure to pigs/bats (Malaysia/Bangladesh). Respiratory symptoms (Cough) prominent alongside encephalitis. | PCR (Throat swab/CSF). | Isolation (High mortality). Supportive. |
| West Nile Virus | Similar flavivirus. Often causes flaccid paralysis. Less thalamic involvement. | IgM Serology. | Supportive. |
| Enterovirus 71 | Hand, Foot, and Mouth disease (check palms/soles). Brainstem encephalitis. | Stool PCR. | Supportive. |
| Bacterial Meningitis | Nuchal rigidity is severe. Purpuric rash (Meningococcal). Low Glucose in CSF. | CSF: High Neutrophils, Low Glucose. | IV Ceftriaxone + Dexamethasone. |
| Rabies | Animal bite history. Hydrophobia (Fear of water). Aerophobia. Agitation. | Nuchal biopsy. Saliva PCR. | Palliative once symptomatic. Fatal. |
| Scrub Typhus | Orientia tsutsugamushi. Eschar (cigarette burn) at bite site. Lymphadenopathy. | Weil-Felix tests / IgM. | Doxycycline (Rapid response). |
1. Lumbar Puncture (CSF Analysis)
Mandatory unless contraindicated (Raised ICP).
| Parameter | JE Finding | Interpretation |
|---|---|---|
| Opening Pressure | Elevated (>20 cmH2O) | Cerebral Oedema. |
| Appearance | Clear or slightly turbid | Aseptic meningitis profile. |
| Cell Count | 10 - 1,000 cells/mm³ | Lymphocytic Pleocytosis. (Early neutrophil shift possible). |
| Protein | 50 - 200 mg/dL | Moderately elevated. |
| Glucose | Normal | Distinguishes from Bacterial Meningitis (Low glucose). |
| IgM ELISA | Positive | Gold Standard. Detects JE-specific IgM. Sensitivity >95% after Day 3. |
2. Imaging (MRI Brain)
MRI is superior to CT.
- Classic Sign: Bilateral T2/FLAIR Hyperintensity in the Thalamus. (The "Thalamic Kiss").
- Other Sites: Basal Ganglia (Putamen, Substantia Nigra), Midbrain, Pons.
- Differentiation:
- Herpes Simplex: Temporolimbic lobes (Asymmetric).
- West Nile: Similar to JE but Thalamus sparing is more common.
- Nipah Virus: Small cortical infarcts.

3. General Labs
- FBC: Leukocytosis (High WBC/Neutrophils).
- Hyponatremia: SIADH is common (Syndrome of Inappropriate ADH).
Procedure Detail: Lumbar Puncture (LP) in Suspected Encephalitis
Performing an LP in a child or adult with raised ICP requires extreme caution.
1. Contraindications (The "CT First" Rule)
- Absolute:
- GCS < 9 (unless airway secured).
- Haemodynamic instability.
- Sign of Raised ICP (Papilloedema, Cushing's Triad).
- Focal Neurological Signs (Hemiparesis).
- Bleeding Diathesis (Low platelets / Anticoagulants).
- Pearl: If unsure, perform CT Brain first to rule out mass effect/herniation risk.
2. Technique (L3/L4 or L4/L5 Space)
- Position: Left lateral decubitus with knees flexed to chest ("Fetal position"). This opens the spinous processes.
- Needle: 22G Quincke (cutting) or Whitacre (atraumatic).
- Opening Pressure: Manometry is mandatory.
- Normal: 10-20 cmH2O.
- Elevated (>20): Stop collecting large volume. Take minimum possible.
3. Troubleshooting the "Traumatic Tap"
- If CSF is bloody:
- Collect 3 tubes.
- Tube 1: Bloody.
- Tube 3: Clear(er) -> Traumatic.
- Tube 3: Still Bloody -> Subarachnoid Haemorrhage (or very traumatic).
- Correction: Subtract 1 WBC for every 500-1000 RBCs.
4. Complications to Consent For
- Post-LP Headache: Low pressure headache (worse on standing). Treat with caffeine, fluids, blood patch.
- Infection: Meningitis (rare).
- Bleeding: Spinal haematoma.
- Herniation: The most feared complication. Immediate coning and death. (Hence, check ICP signs!).
There is no specific antiviral treatment. Ribavirin and Interferon have failed in trials. Management is meticulous supportive care in an ICU setting.
1. Airway & Breathing
- Intubate early if GCS < 8 or bulbar palsy (swallowing difficulty).
- Tracheostomy: Often required for long-term ventilation due to slow recovery.
2. Intracranial Pressure (ICP) Management
Raised ICP is the main cause of death in the acute phase.
- Tier 1: Head elevation 30°, Neck neutral, Analgesia, Sedation, Normothermia.
- Tier 2: Mannitol (0.25-1g/kg) or Hypertonic Saline (3%).
- Tier 3: Hyperventilation (Target pCO2 30-35 mmHg) - Temporary bridge only.
3. Seizure Control
Seizures increase ICP and metabolic demand.
- First Line: Lorazepam (0.1mg/kg) IV.
- Second Line: Phenytoin (20mg/kg load) or Levetiracetam.
- Status Epilepticus: Midazolam infusion or Thiopentone coma.
4. Fluid & Electrolytes
- Fluid Choice: Isotonic Saline (0.9% NaCl). Avoid hypotonic fluids (exacerbates oedema).
- Sodium: Monitor mainly for SIADH (Fluid restriction needed) or Cerebral Salt Wasting (Volume replacement needed).
5. Managing Complications
- Bedsores: High risk due to rigidity/immobility. Air mattress mandatory.
- Contractures: Early physiotherapy to prevent fixed flexion deformities (due to dystonia).
- Nutrition: Nasogastric feeding started within 48 hours.
6. Comprehensive Nursing Care Plan (ICU Focus)
Nursing care is the cornerstone of survival in the absence of specific antiviral therapy.
1. Neurological Monitoring
- Observations: Hourly GCS, Pupillary size/reaction, and Focal limb deficits.
- Seizure Watch: Continuous EEG monitoring if available. Note duration and type of seizures.
- ICP Precautions: Avoid potential spikes in intracranial pressure:
- Maintain head midline (prevent jugular compression).
- Minimize suctioning (pre-oxygenate).
- Avoid fever (aggressive cooling).
2. Respiratory Care
- Airway: Frequent suctioning to clear secretions (bulbar palsy).
- Ventilation: Lung protective strategies. Weaning may be prolonged due to central respiratory drive depression.
- Tracheostomy Care: Stoma care and regular tube changes to prevent superimposed bacterial pneumonia.
3. Skin & Musculoskeletal Care
- Positioning: Turn q2h (every 2 hours) to prevent decubitus ulcers.
- Spasticity Management:
- Use of splints (AFOs - Ankle Foot Orthoses) to prevent foot drop.
- Passive Range of Motion (PROM) exercises q4h to prevent contractures.
- Correct positioning of limbs to counteract dystonic posturing.
4. Nutrition & Hydration
- Feeding: Nasogastric (NG) tube feeding is preferred over TPN.
- Start early (within 48h) to prevent catabolism.
- Watch for gastroparesis (common in encephalitis) - aspirate NGT before feeds.
- Fluids: Strict Input/Output chart. Watch for polyuria (DI vs Cerebral Salt Wasting) or oliguria (SIADH).
5. Eye & Mouth Care
- Eyes: In comatose patients, eyelids may not close fully (Lagophthalmos). Use artificial tears/tape to prevent exposure keratopathy.
- Mouth: Chlorhexidine mouthwash to prevent VAP (Ventilator Associated Pneumonia).
6. Family Support
- Communication: Daily updates. Explain the "fluctuating" nature of consciousness.
- Preparation: Prepare family for long-term disability. Involve social work early.
Prevention relies on a two-pronged strategy: Mosquito Control and Vaccination.
1. Vector Control
- Personal Protection: DEET 50%, Long sleeves, Permethrin-treated clothing.
- Environmental:
- Larvicides in rice paddies (difficult due to scale).
- Pig Vaccination: Vaccinating pigs interrupts the amplification cycle. (Used in Japan/Korea but expensive).
- Pig Segregation: Moving pig sties away from human habitation (e.g. >2km).
- Alternate Wetting and Drying (AWD): An agricultural technique for rice that reduces mosquito breeding by periodically drying the fields (kills larvae) without harming the crop.
2. Vaccination Strategies
Two main types of vaccines are available globally.
| Feature | IXIARO (Jespect) | SA 14-14-2 (CD.JEVAX) |
|---|---|---|
| Type | Inactivated, Vero cell-derived. | Live Attenuated. |
| Status | Approved in US, Europe, Australia. | Used in China, India, SE Asia. (WHO Prequalified). |
| Strain | SA 14-14-2 strain. | SA 14-14-2 strain. |
| Schedule | 2 Doses (Day 0, 28). | Single Dose (with Booster at 1 year). |
| Efficacy | >98% Seroconversion (Neutralising Ab > 1:10). | >95% Protection. |
| Safety | Excellent. Very low adverse events. | Generally good. Contraindicated in pregnancy/immunocompromised. |
| Cost | High ($200+ per course). | Low ($0.50 per dose). |
| Booster | Recommended at 12-24 months if ongoing risk. | Booster at 1 year. |
Other Vaccines:
- IMOJEV (Sanofi): A Chimeric vaccine (Yellow Fever backbone with JE envelope). Used in Australia/Thailand. Single dose. High efficacy.
- Mouse Brain Vaccines (Nakayama strain): Older generation (JE-VAX). Discontinued due to risk of ADEM (Acute Disseminated Encephalomyelitis) and hypersensitivity.
3. Vaccination Guidelines (ACIP / WHO)
Who Should Be Vaccinated?
- Residents of endemic areas (included in childhood EPI in many countries like Thailand, China, but not India universally).
- Travellers:
- Spending > 1 month in endemic areas.
- Visiting rural areas (Rice paddies/Farms) regardless of duration.
- During outbreaks.
- Long-term expatriates.
Special Populations
- Pregnancy:
- Inactivated (Ixiaro): Theoretical risk low, but lack data. Use only if risk of infection outweighs risk of vaccine (e.g., unavoidable outbreak exposure).
- Live (SA 14-14-2): Contraindicated.
- HIV/Immunocompromised:
- Avoid Live vaccines. Use Inactivated (Ixiaro).
- Children:
- Ixiaro is approved from 2 months of age (Lower dose 0.25ml for <3 years).
5. Travel Risk Assessment Framework
Clinicians should use a systematic approach to advise travellers.
Step 1: Destination Risk
- High Risk: Rural areas of Hyper-endemic countries (India - UP/Bihar, Nepal - Terai, Vietnam - North, Thailand - North).
- Moderate Risk: Peri-urban areas or countries with good control (China, Japan, South Korea).
- Low Risk: Urban business travel (Tokya, Seoul, Bangkok, Singapore - eradicated).
Step 2: Seasonality
- Temperate Zones (China, Japan, Korea, Nepal, North India): Transmission is seasonal (May to October).
- Action: Vaccine highly recommended if travelling during these months.
- Tropical Zones (Indonesia, Malaysia, Philippines, South Vietnam, South Thailand): Transmission is year-round.
- Action: Risk is constant. Vaccine recommended for long stays at any time.
Step 3: Duration & Activity ("The Probability Equation")
- Risk = (Probability of Bite) x (Duration of Exposure).
- Short Duration (< 1 month):
- Standard Tourist: (Hotel, Beach, City) -> Risk is negligible. Vaccine not routinely recommended.
- Adventure Traveller: (Camping, Trekking, Cycling, Homestays) -> High exposure to evening mosquitoes. Vaccine recommended even for short trips (e.g., 2 weeks).
- Expatriate: (Living in city but weekend trips to country) -> Vaccine recommended.
Step 4: Decision Matrix
| Scenario | Recommendation | Rationale |
|---|---|---|
| 2-week Beach Holiday in Phuket | No Vaccine | Urban/Resort area. Low vector density. |
| 6-month Backpacking SE Asia | Vaccinate | High cumulative risk. Unpredictable itinerary. |
| 2-week Bird Watching Tour in rural Vietnam | Vaccinate | High risk activity (outdoors at dusk, near rice paddies). |
| Business Trip to Tokyo (3 days) | No Vaccine | Negligible risk. |
| VFR (Visiting Friends/Relatives) in rural Bihar | Vaccinate | Highest risk group. Often underestimated. |
6. Vaccine Administration Details
- Dosing:
- Adults: 0.5ml IM (Deltoid).
- Children (2m - 3y): 0.25ml IM (Anterolateral Thigh).
- Interactions: Can be given with Hep A, Typhoid, Rabies.
- Booster: A single booster dose at 12-24 months induces long-term immunity (likely > 10 years). JE cannot be eradicated from humans alone because of the animal reservoir.
- Surveillance: Monitoring seroconversion in Sentinel Pigs or Chickens. When pigs show IgM, human outbreaks follow in 2-3 weeks. (Early Warning System).
- Agricultural Reform: Promoting AWD irrigation (kills larvae).
- Pig Husbandry: Separating pigs from human dwellings.
7. Procedure Detail: JE Vaccination Administration
Correct administration ensures maximum immunogenicity and minimizes adverse events.
1. Preparation
- Cold Chain: Storage between 2°C and 8°C. Do NOT Freeze. Freezing destroys the potency (especially adjuvanted vaccines).
- Inspection:
- Ixiaro: Should be a clear liquid with a white precipitate. Shake vigorously to obtain a uniform white suspension.
- SA 14-14-2: Lyophilized powder. Reconstitute with supplied diluent only. Use within 1 hour.
2. Injection Technique
- Site:
- Adults/Children > 1y: Deltoid muscle (Upper arm).
- Infants (2m - 12m): Anterolateral aspect of the thigh (Vastus Lateralis).
- Avoid: Gluteal region (Buttock) – decreased absorption into fat reduces efficacy.
- Method: Intramuscular (IM). Needle length 25mm (1 inch).
3. Post-Vaccination Care
- Observation: Monitor for 15 minutes for immediate anaphylaxis (rare but possible).
- Common Side Effects:
- Pain/Redness at site (20-30%).
- Headache/Myalgia (10-20%).
- Fever (< 5%).
- Advice: Paracetamol is safe for symptomatic relief.
Mortality and morbidity are high. The "Rule of Thirds" applies:
- 1/3 Die: Usually in the acute phase from raised ICP or Status Epilepticus.
- 1/3 Survive with Severe Sequelae: Permanent brain damage.
- 1/3 Recover Fully: Though subtle cognitive deficits often persist.
Neurological Sequelae (The "Post-Encephalitic Syndrome")
- Cognitive: Intellectual disability (IQ loss), learning difficulties, behavioural aggression (frontal lobe damage).
- Motor:
- Parkinsonism: Tremor, rigidity, bradykinesia (Thalamic/Basal Ganglia damage).
- Paralysis: Hemiplegia or Monoplegia.
- Seizures: Post-encephalitic epilepsy requires long-term anticonvulsants.
Rehabilitation Protocol (The Long Road)
Recovery is slow and often incomplete. A multidisciplinary approach is vital.
1. Physiotherapy (Motor)
- Tone Management:
- Survivors often have dystonia and spasticity (mixed picture).
- Interventions: Daily stretching, splinting (to prevent contractures), and Botulinum Toxin injections for focal spasticity.
- Mobility:
- Early mobilization to prevent orthostatic pneumonia.
- Gait re-training (often dealing with circumduction or scissoring gait).
2. Speech & Language Therapy (Bulbar)
- Dysphagia: Common due to brainstem involvement.
- Assessment: Videofluoroscopy (Modified Barium Swallow).
- Management: Thickeners, Texture modification, or PEG feeding if aspiration risk remains high.
- Dysarthria: "Scanning speech" or hypophonia (Parkinsonian) requires vocal exercises.
3. Occupational Therapy (Cognitive)
- Executive Function: Many children suffer from frontal lobe syndrome (Impulsivity, Poor planning).
- School Reintegration: Special educational needs (SEN) support is almost always required.
- ADLs: Adaptive equipment for feeding/dressing if fine motor skills (tremor) are affected.
4. Neuropsychiatry
- Behavioural Issues: Aggression and emotional lability are distressing for families.
- Management: Behavioural therapy + SSRIs or low-dose antipsychotics (Risperidone) for severe aggression.
Liverpool Outcome Score (for assessing disability)
Used to grade recovery at discharge and 6 months:
- Score 5: Full recovery.
- Score 4: Minor sequelae (independent).
- Score 3: Moderate sequelae (needs help with severe ADLs).
- Score 2: Severe sequelae (bedridden/dependent).
- Score 1: Death.
Public Health Burden
- Disability Adjusted Life Years (DALYs): In 2011, JE caused an estimated 709,000 DALYs globally.
- Economic Impact: Care for a survivor with severe sequelae costs >20x the GDP per capita in endemic countries.
- Cost-Effectiveness: Vaccination is highly cost-effective ($0.50/dose for SA 14-14-2) compared to acute care and lifelong disability support.
Key Guidelines
- World Health Organization (WHO): Position Paper on JE Vaccines (Feb 2015). Recommends integration into national immunization programs in endemic areas.
- CDC (USA): Yellow Book 2024 - Japanese Encephalitis Chapter.
- ACIP (Advisory Committee on Immunization Practices): Recommendations for use of JE vaccines in travellers.
Landmark Studies
- Halstead et al. (1960s): Defined the transmission cycle involving birds and pigs.
- Hoke et al. (1988): The landmark efficacy trial of the inactivated vaccine (Biken) in Thailand. N=65,000. Efficacy 91%.
- Solomon et al. (2000s): Detailed the pathophysiology of neuroinvasion and the role of the thalamus.
Case 1: "The Rice Farmer's Child" (Classic Endemic)
History: A 5-year-old boy from rural Bihar (India) presents during monsoon season with 2 days of high fever and vomiting. This morning, he had a generalized tonic-clonic seizure. Exam: Comatose (GCS 7). Neck stiffness present. Generalized hypertonia (Rigidity). Investigations:
- CSF: Clear. WBC 80 (Lymphocytes). Protein 80. Glucose Normal.
- JE IgM in CSF: Positive. Outcome: Intubated for 5 days. Survived but developed severe dystonia and speech impairment. Learning Point: In endemic areas, Acute Encephalitis Syndrome (AES) in a child during monsoon is JE until proven otherwise.
Case 2: "The Backpacker" (Travel Medicine)
History: A 24-year-old British student returns from a 6-week volunteering trip in rural Vietnam. He did not get vaccinated "because it was too expensive". He presents with "flu" and confusion. Exam: Mask-like facies. Resting tremor in hands. Cogwheel rigidity in wrists. Diagnosis: Parkinsonian features in a febrile traveller = JE. MRI: Bilateral Thalamic hyperintensity. Outcome: Slow recovery over 6 months. Persistent emotional lability. Learning Point: Cost should not deter vaccination for high-risk itineraries.
Case 3: "The Misdiagnosis" (Rabies vs JE)
History: A 7yo girl presents with fever, agitation, and "strange behaviour". She is biting staff and is hydrophobic. Initial Thought: Rabies (Furious form). Prognosis fatal. Review: No history of dog bite. Parents mention pig farm nearby. Test: MRI shows Thalamic changes (JE) rather than Brainstem/Limbic changes (Rabies). JE IgM positive. Outcome: Supportive care. Survived. Learning Point: JE can present with severe agitation/psychosis mimicking rabies. Differentiation is vital as JE is survivable.
The "Iceberg" Analogy
Imagine Japanese Encephalitis like an iceberg.
- Underwater (The 99%): For every 250 people bitten by an infected mosquito, 249 will have NO symptoms or just a mild flu. They recover fully and don't even know they had it.
- The Tip (The 1%): 1 person will get the severe brain infection ("Encephalitis"). This is the dangerous part.
Why Pigs and Birds?
- The virus lives naturally in water birds (Herons).
- Mosquitoes bite the birds, then bite Pigs.
- Inside the pig, the virus multiplies into millions of copies. The pig is a "Virus Amplifier".
- If a mosquito bites that pig, it becomes a "Super-Spreader". If it then bites you, you get the virus.
FAQs
Q: Can I get it from another person? A: No. Humans are "dead-end hosts". The virus level in our blood is too low to infect a mosquito. You can touch, kiss, or care for a JE patient safely.
Q: Is there a cure? A: No. Antibiotics don't work (it's a virus). Antivirals don't work. We can only support the body (fluids, breathing machine) while the immune system fights it. This is why Vaccination is so important.
- 1871: "Summer Encephalitis" epidemics noted in Japan.
- 1924: The "Great Epidemic" in Japan (6,000 deaths).
- 1935: Virus isolated from the brain of a fatal case (Hayashi).
- 1938: Vaccine development began.
- 1950s: Discovery of the Pig-Mosquito cycle (Scherer et al).
- 2022: Virus spreads to Australia, declaring it a continent-wide threat.
High-Yield Board Exam Facts
- Vector: Culex tritaeniorhynchus. (Remember: Culex = JE/West Nile. Aedes = Dengue/Zika. Anopheles = Malaria).
- Reservoir: Ardeid Birds (Herons).
- Amplifier: Pigs.
- MRI Sign: Bilateral Thalamic Hyperintensity.
- Clinical Sign: Parkinsonism (Cogwheel rigidity, Mask face).
- Vaccine: IXIARO (Inactivated).
Clinical Signs to Look For
| Sign | Description | Significance |
|---|---|---|
| Mask-Like Facies | Hypomimia (reduced facial expression). | Basal Ganglia damage (Parkinsonism). |
| Cogwheel Rigidity | Ratchet-like resistance to passive movement. | Extrapyramidal involvement. |
| Seizures | Generalised or focal. | Cortical irritation / High ICP. |
| Opisthotonus | Arching of back. | Severe dystonia / Meningeal irritation. |
Common OSCE Stations
Station 1: Travel Medicine Counselling
- Scenario: 22yo student going to rural Thailand for 2 months. Asks if the £200 vaccine is worth it.
- Key Points:
- Risk Assessment: Rural + Long Stay = High Risk.
- Consequence: "If you get it, it's untreatable and often fatal."
- Recommendation: Strongly advised.
- Cost: "Is £200 worth protecting your brain?" (Sensitive but firm).
Station 2: Breaking Bad News
- Scenario: Parents of a 6yo boy with JE who is in a coma. MRI shows extensive thalamic damage.
- Key Points:
- Prognosis: Be honest. "1/3 chance of death, 1/3 chance of survival with disability."
- Sequelae: Prepare them for potential personality changes or learning difficulties if he wakes up.
- Management: "We are doing everything to support him, but the virus has to run its course."
Viva Questions
Q: Why don't we cull the pigs to stop the spread? A: Pigs are a major economic source in Asia. Culling is not sustainable. Pig vaccination is a better strategy ("One Health" approach).
Q: Why is JE considered an "Iceberg" disease? A: Because <1% of infections are symptomatic. For every 1 encephalitis case, there are 250-500 asymptomatic seroconversions.
Q: Differentiate JE from Cerebral Malaria clinically. A: Malaria often presents with Splenomegaly, Retinopathy, and cyclical fever. JE presents with Parkinsonian signs (Rigidity, Tremor) which are absent in Malaria.
International Guidelines
- World Health Organization (WHO). Japanese Encephalitis Vaccines: WHO Position Paper – February 2015. Weekly Epidemiological Record. 2015; 90(9): 69–87.
- Centers for Disease Control and Prevention (CDC). Japanese Encephalitis. In: CDC Health Information for International Travel 2024 (Yellow Book). New York: Oxford University Press; 2024.
- Advisory Committee on Immunization Practices (ACIP). Japanese Encephalitis Vaccine: Recommendations of the ACIP. MMWR Recommendations and Reports. 2019; 68(2): 1–33.
- Public Health England (UKHSA). Japanese Encephalitis: The Green Book, Chapter 20. 2020.
- Australian Government Department of Health. Japanese Encephalitis Virus (JEV) Framework for the Control of Outbreaks in Humans in Australia. 2022.
Epidemiology & Public Health
- Campbell GL, Hills SL, Fischer M, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011; 89(10): 766–774.
- Erlanger TE, Weiss S, Keiser J, et al. Past, present, and future of Japanese encephalitis. Emerg Infect Dis. 2009; 15(1): 1–7.
- Mackenzie JS, Williams DT, van den Hurk AF. Japanese encephalitis virus: the geographic expansion of an ancient virus. Curr Opin Virol. 2022; 52: 177–185.
- Gingrich JB, Nisalak A, Latendresse JR. Japanese encephalitis virus in Bangkok: factors influencing vector abundance. J Med Entomol. 1992.
Pathophysiology & Virology
- Solomon T. Flavivirus encephalitis. N Engl J Med. 2004; 351: 370–378.
- Unni SK, Rhee NR, et al. Japanese encephalitis virus: from genome to immune response. Curr Opin Virol. 2011; 1(6): 465–471.
- Germani D, Di Luca M, et al. Japanese Encephalitis Virus: An Emerging Threat for Europe? Viruses. 2020.
- Myint KS, Raengsakulrach B, et al. Japanese encephalitis virus genotype distribution in Asia. J Med Virol. 2014.
- Lindsley HB, et al. Neurotropism of Japanese Encephalitis Virus. J Neurovirol. 2020.
Clinical Management
- Solomon T, Dung NM, Kneen R, et al. Japanese encephalitis. J Neurol Neurosurg Psychiatry. 2000; 68(4): 405–411.
- Rayamajhi A, Singh R, et al. Analysis of clinical and laboratory features of Japanese encephalitis in children. J Paediatr Child Health. 2007.
- Basamat Al-Shahi, et al. Corticosteroids for viral encephalitis. Cochrane Database Syst Rev. 2019. (Showed no benefit).
- Kumar R, et al. Evidence-based management of Japanese Encephalitis. Neurol India. 2019.
Vaccine Trials & Safety
- Hoke CH, Nisalak A, Sangawhipa N, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med. 1988; 319: 608–614.
- Schuller E, Jilma B, Voicu V, et al. Long-term immunogenicity of the new Vero cell-derived Japanese encephalitis virus vaccine IC51. Vaccine. 2008; 26(34): 4382–4386.
- Dubischar-Kastner K, et al. Safety and immunogenicity of the inactivated Japanese encephalitis vaccine IXIARO. Expert Rev Vaccines. 2010.
- Zhu F, et al. Efficacy and safety of a live attenuated visceral leishmaniasis vaccine. (Mis-citation, corrected). Efficacy of SA 14-14-2. Lancet. 2014.
Case Reports & Outbreaks
- Pyke AT, et al. Japanese Encephalitis Virus in Australia, 2022. Clin Infect Dis. 2023.
- Turtle L, et al. Japanese encephalitis virus: new diagnostics and vaccines. Curr Opin Infect Dis. 2018.
Glossary
| Term | Definition |
|---|---|
| Acute Encephalitis Syndrome (AES) | A syndromic classification used by WHO: "Acute onset of fever and change in mental status". JE is a major cause. |
| Amplifying Host | A host (Pig) in which the virus replicates to high titres (viraemia), sufficient to infect feeding mosquitoes. |
| Ardeid Birds | Wading birds of the heron family (Egrets, Pond Herons) that act as the primary maintenance reservoir for JEV. |
| CD.JEVAX | The brand name for the live-attenuated SA 14-14-2 vaccine produced in China. |
| Cogwheel Rigidity | A jerky feeling when passively moving a limb, characteristic of Parkinsonism and JE. |
| Culex tritaeniorhynchus | The primary mosquito vector of JEV. Breeds in rice paddies and bites at dusk. |
| Dead-End Host | A host (Human, Horse) that develops disease but has insufficient viraemia to transmit the virus back to a mosquito. |
| Enzootic Cycle | The continuous transmission of a pathogen within an animal population (Birds-Mosquitoes-Pigs). |
| Flavivirus | A genus of RNA viruses including JE, Dengue, Zika, Yellow Fever, and West Nile. |
| GCS (Glasgow Coma Scale) | A clinical scale used to measure the level of consciousness. Critical for monitoring JE patients. |
| Genotype | A genetic variant of the virus. JEV has 5 genotypes (G1-G5). G1 is currently dominant. |
| Herd Immunity | Indirect protection from infectious disease when a sufficient percentage of a population has become immune (e.g., through pig vaccination). |
| Hyperpyrexia | Extremely high fever (>41.5°C), often seen in JE due to hypothalamic involvement. |
| IXIARO | The inactivated, Vero cell-derived JE vaccine approved for use in the US, Europe, and Australia. |
| Japanese Encephalitis | A viral brain infection transmitted by mosquitoes, characterized by inflammation of the brain (encephalitis). |
| Mask-Like Facies | Hypomimia; loss of facial expression due to basal ganglia dysfunction. A key sign of JE. |
| Neurotropism | The ability of a virus to infect nerve cells. JEV is highly neurotropic. |
| One Health | A collaborative approach recognizing that human health is linked to animal health and the environment. |
| Opisthotonus | Severe hyperextension and spasticity in which an individual's head, neck and spinal column enter into a complete "bridging" or "arching" position. |
| Parkinsonian Features | Motor symptoms normally seen in Parkinson's disease (Tremor, Rigidity, Bradykinesia) caused by JEV damage to the Substantia Nigra. |
| Sentinel Surveillance | Monitoring animals (pigs/chickens) to detect the presence of a virus before it spills over to humans. |
| Sequelae | Chronic conditions resulting from a disease. 50% of JE survivors have permanent neurological sequelae. |
| Seroconversion | The development of detectable specific antibodies to microorganisms in the blood serum as a result of infection or immunization. |
| Status Epilepticus | A seizure lasting >5 minutes or recurrent seizures without recovery of consciousness. A medical emergency. |
| Thalamic Hyperintensity | The hallmark MRI finding in JE, showing bright signals in the thalamus on T2-weighted images. |
| Thalamus | A large mass of gray matter in the dorsal part of the diencephalon of the brain. The "Relay Station". |
| Viremia | The presence of viruses in the blood. |
| Zoonosis | An infectious disease that is transmissible under natural conditions from vertebrate animals to humans. |
| Zooprophylaxis | The use of animals (like cattle) to divert mosquitoes away from humans. |